A variety of studies have demonstrated that bone marrow stromal cells play an important role in regulating acute lymphoblastic leukemia (ALL) 1 and chronic lymphocytic leukemia (CLL) cell survival and response to chemotherapy. [2] [3] The significance of the microenvironment in CLL, along with new insights into its pathogenesis, has been extensively reviewed. 4 While the importance of the bone marrow microenvironment in leukemic progression is not disputed, several details of the survival pathways initiated by bone marrow stromal cells remain under investigation.
We recently investigated the role of vascular endothelial growth factor (VEGF) in regulating ALL cell survival 5 because VEGF is a stromal cell derived growth factor to which the hematopoietic cells in the bone marrow are exposed. The goal of our previous study was, in part, to determine whether VEGF influenced either Bcl-2 protein expression or activity as a required component regulating in vitro chemotherapy response. 5 Based on reports that described Bcl-2 phosphorylation as a requirement for optimal antiapoptotic function, we specifically evaluated VEGF-induced Bcl-2 phosphorylation at serine 70 in ALL cells. Collectively, our data suggested a role for VEGF regulation of Bcl-2 phosphorylation and chemoresistance in children ALL cells. 5 We subsequently sought to determine if VEGF influenced phosphorylation of Bcl-2 protein in human CLL cells. While ALL and CLL cells both benefit from stromal cell interaction, it cannot be assumed that the survival pathways supported by stromal cell derived signals are identical, given the distinct cellular differences between these diseases. Other investigators have documented the presence of VEGF receptors on CLL cells 6, 7 and have implicated downstream signaling that involves STAT1 and STAT3 in VEGF-mediated resistance to programmed cell death. 6 In addition, elevated serum levels of VEGF are correlated with an unfavorable prognosis. 8 Based on these published observations and our investigation of VEGF-induced phosphorylation of Bcl-2 in ALL, we investigated the influence of VEGF on CLL cell survival and phosphorylation of Bcl-2.
þ mononuclear cells (MNCs) from three patients with CLL were isolated from peripheral blood by separation on a lymphopaque gradient for analysis. Pretreatment of the CLL cells with recombinant VEGF reduced the amount of apoptosis induced by exposure to 4-hydroperoxycyclphosphamide (4-HC), the active metabolite of cyclophosphamide ( Figure 1 ). Untreated control CLL cells had approximately 5% spontaneous apoptosis, measured by Annexin-V-FITC labeling and subsequent flow cytometric analysis. The incidence of apoptosis was greater than 18% following a 12-h exposure to 4-HC. Pretreatment with recombinant VEGF prior to 4HC exposure reduced the initiation of apoptosis by approximately 50% (Figure 1) .
To determine whether Bcl-2 protein is phosphorylated, and whether the phosphorylation status is influenced by VEGF, CLL cells were initially serum starved overnight. Subsequently, cells were exposed to 4-HC alone or VEGF alone, or pre-treated with VEGF followed by 4-HC treatment. Similar to ALL cells that we evaluated in our earlier study, Bcl-2 protein was shown to be constitutively phosphorylated in unstimulated cells (Figure 2) . In contrast to ALL cells, however, recombinant VEGF did not increase the amount of phosphorylated Bcl-2 that was detected in the CLL samples (Figure 2 ). These data suggest that, while VEGF does increase CLL survival in this in vitro model, the prosurvival effect may not be mediated through the regulation of Bcl-2 function. In addition, the phosphorylation status of Bcl-2 did not correlate with survival in this pilot study.
Although it did not appear that VEGF affected the phosphorylation of Bcl-2 protein in CLL cells, we completed additional testing to increase our confidence in this observation. In our earlier study, we substantiated the recombinant VEGF effects on Bcl-2 phosphorylation by neutralizing VEGF in stromal cell supernatants with a resultant loss of phosphorylation of Bcl-2 in ALL cells cultured in the conditioned media. 5 A similar strategy was undertaken with the CLL cells. CLL cells were cultured in either control medium or stromal cell conditioned medium that was concentrated and subsequently supplemented with either a neutralizing antibody specific for VEGF, or a matched isotype control antibody at the identical concentration (Figure 3) . Consistent with the results obtained using recombinant VEGF, concentrated stromal cell conditioned medium did not significantly increase the amount of phosphorylated Bcl-2 protein when analyzed by Western blot analysis.
These data do not diminish the importance of either the stromal cell microenvironment, or stromal cell derived VEGF in the progression of CLL or its response to treatment. Rather, they highlight a potential survival pathway difference between ALL and CLL. Further, they underscore the fact that while the same initiating survival signal may have a common end point in two different diseases, the mechanism by which the signal influences a cell's fate is potentially very different. Given the increased focus on, and ability to, distinguish sub-types within broad disease categories, including ALL and CLL, potentially further delineations of survival signaling will be identified as well that correlate with very specific molecular, genetic and phenotypic characteristics. Collectively, these differences between leukemic cells may influence their response to the stromal cell microenvironment. VEGF promotes primary CLL cell survival during chemotherapy treatment. Primary CLL cells were in vitro cultured in serumfree Iscove's medium in the presence of 5 mM Gö 6983 overnight. Cells were then pretreated with 100 ng/ml of VEGF followed by 4-HC exposure (10 mg/ml) for 12 h. Flow cytometric analysis of Annexin-V staining was completed.
Figure 2
VEGF-induced survival of CLL cells is independent of Bcl-2 phosphorylation. Primary CLL samples identical to those described in Figure 1 were lysed and protein quanitated. Total cellular extracts were separated on 12% SDS-PAGE gel and transferred to nitrocellulose membrane. The blot was first probed with phospho-Bcl-2 antibody then stripped and reprobed with total Bcl-2 and GAPDH specific antibodies.
Figure 3
Stromal cell conditioned medium does not influence Bcl-2 phosphorylaton. Western blot of primary CLL cells incubated for 24 h in P156 stromal cell conditioned medium (SCCM) or control concentrated medium (Ctrl Med) in the presence or absence of anti-VEGF/isotype antibodies.
